Revolution Medicines is set to ship its experimental drug, daraxonrasib, aimed at treating pancreatic cancer. The announcement comes from CEO Mark Goldsmith.
Goldsmith indicated that the company plans to submit the drug for FDA approval in the near future, although specific timelines have not been disclosed.
This development marks a significant step in the company's efforts to address pancreatic cancer, a disease known for its challenging prognosis.